KRAS-mutatedcancers were considered undruggable for a long time.The FDA-approved non-small cell lung cancer drugs, sotorasib and adagrasib, alongwith the more recently discovered MK-1084, covalently target the acquired cysteine in the K-RasG12C mutation, thereby locking K-Ras in a signaling-incompetent stateand effectively inhibiting its activity. Here, KRAS is linked to non-small cell lung carcinoma.